Recurrent translocation (10;17)(p15;q21) in acute poorly differentiated myeloid leukemia likely results in ZMYND11-MBTD1 fusion

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1189-1190

  De Braekeleer, Etienne ^a   Auffret, Régis ^a   Douet Guilbert, Nathalie ^a,b,c   Basinko, Audrey ^c   Le Bris, Marie Josée ^c   Morel, Frédéric ^a,b,c   De Braekeleer, Marc ^a,b,c  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b French Blood Agency   (France)

^c CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; CARRIER PROTEIN; MBTD1 PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOPROTEIN; ZMYND11 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ASTHENIA; BONE MARROW TRANSPLANTATION; CASE REPORT; CHROMOSOME 10; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; KARYOTYPE; LEG PAIN; LETTER; MALE; MBTD1 GENE; METAPHASE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; ZMYND11 GENE; CANCER GRADING; FATALITY; GENE TRANSLOCATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CARRIER PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84899758455     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820292     Document Type: Letter

References (22)

1. Tempescul A, Guillerm G, Douet-Guilbert N, et al. Translocation (10;17)(p15;q21): Recurrent anomaly in acute myeloblastic leukemia. Cancer Genet Cytogenet 2007; 172: 74-76.
2. Dicker F, Haferlach C, Kern W, et al. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308-1316.
3. Pollak C, Hagemeijer A. Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders. Leukemia 1987; 1: 541-548.
4. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C , van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 2003; 101: 837-845.
5. Shah D, Bond M, Kilby AM, et al. Widespread bone disease in acute myeloid leukaemia. Leuk Lymphoma 2001; 42: 1309-1314.
6. Silva ML, Ornellas de Souza MH, Ribeiro RC, et al. Cytogenetic analysis of 100 consecutive newly diagnosed cases of acute lymphoblastic leukemia in Rio de Janeiro. Cancer Genet Cytogenet 2002; 137: 85-90.
7. ISCN (2009). A n International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2009.
8. De Braekeleer E, Douet-Guilbert N, Basinko A, et al. Using bacterial artificial chromosomes in leukemia research: The experience at the university cytogenetics laboratory in Brest, France. J Biomed Biotechnol 2011; 2011: 329471.
9. Hateboer G, Gennissen A, Ramos Y F, et a l. B S69, anovel adenovirus E1A-Associated protein that inhibits E1A transactivation. EMBO J 1995; 14: 3159-3169.
10. Masselink H, Bernards R. The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. Oncogene 2000; 19: 1538-1546.
11. Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO gene. Gene 1998; 212: 103-109.
12. Lutterbach B, Sun D, Schuetz J, et al. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol 1998; 18: 3604-3611.
13. Wang J, Hoshino T, Redner RL, et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95: 10860-10865.
14. Ansieau S, Leutz A. The conserved Mynd domain of BS69 binds cellular and oncoviral proteins through a common PXLXP motif. J Biol Chem 2002; 277: 4906-4910.
15. Ladendorff NE, Wu S, Lipsick JS. BS69, an adenovirus E1Aassociated protein, inhibits the transcriptional activity of c-Myb. Oncogene 2001; 20: 125-132.
16. Eryilmaz J, Pan P, Amaya M F, et al. Structural studies of a four-MBT repeat protein MBTD1. PLoS One 2009; 4: E7274.
17. Boccuni P, MacGrogan D, Scandura JM, et al. The human L(3) MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). J Biol Chem 2003; 278: 15412-15420.
18. Trojer P, Li G, Sims RJ III, et al. L3MBTL1, ahistone- methylationdependent chromatin lock. Cell 2007; 129: 915-928.
19. Guo Y, Nady N, Qi C, et al. Methylation-state-specific recognition of histones by the MBT repeat protein L3MBTL2. Nucleic Acids Res 2009; 37: 2204-2210.
20. Nady N, Krichevsky L, Zhong N, et al. Histone recognition by human malignant brain tumor domains. J Mol Biol 2012; 423: 702-718.
21. Arai S, Miyazaki T. Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1. EMBO J 2005; 24: 1863-1873.
22. Gurvich N, Perna F, Farina A, et al. L3MBTL1 polycomb protein, acandidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci USA 2010; 107: 22552-22557.